(Q42978711)

12 November 2017

title

Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms (English)

1 reference

12 November 2017

1 reference

Emiko Sugiyama

1

1 reference

12 November 2017

Nahoko Kaniwa

2

1 reference

12 November 2017

Su-Ryang Kim

3

1 reference

12 November 2017

Ryuichi Hasegawa

4

1 reference

12 November 2017

Yoshiro Saito

5

1 reference

12 November 2017

Hideki Ueno

6

1 reference

12 November 2017

Takuji Okusaka

7

1 reference

12 November 2017

Masafumi Ikeda

8

1 reference

12 November 2017

Chigusa Morizane

9

1 reference

12 November 2017

Shunsuke Kondo

10

1 reference

12 November 2017

Noboru Yamamoto

11

1 reference

12 November 2017

Tomohide Tamura

12

1 reference

12 November 2017

Junji Furuse

13

1 reference

12 November 2017

Hiroshi Ishii

14

1 reference

12 November 2017

Teruhiko Yoshida

15

1 reference

12 November 2017

Nagahiro Saijo

16

1 reference

12 November 2017

Jun-Ichi Sawada

17

1 reference

12 November 2017

publication date

1 August 2010

1 reference

Clinical Pharmacokinetics

12 November 2017

published in

1 reference

12 November 2017

volume

49

1 reference

12 November 2017

issue

8

1 reference

12 November 2017

page(s)

549-558

1 reference

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

12 November 2017

cites work

1 reference

12 December 2020

Severe non-haematological toxicity after treatment with gemcitabine

1 reference

12 December 2020

Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1)

1 reference

12 December 2020

Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate

1 reference

12 December 2020

Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines.

1 reference

12 December 2020

Mammalian nucleoside transporters

1 reference

12 December 2020

Retrospective analysis of adverse drug reactions induced by gemcitabine treatment in patients with non-small cell lung cancer

1 reference

12 December 2020

Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment

1 reference

12 December 2020

Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients.

1 reference

12 December 2020

Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer

1 reference

12 December 2020

Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients

1 reference

12 December 2020

Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine

1 reference

12 December 2020

Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin

1 reference

12 December 2020

Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples

1 reference

12 December 2020

Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation

1 reference

12 December 2020

Gemcitabine--a safety review

1 reference

12 December 2020

Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.

1 reference

12 December 2020

Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts.

1 reference

12 December 2020

Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients

1 reference

12 December 2020

Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism

1 reference

12 December 2020

Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method.

1 reference

12 December 2020

Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants.

1 reference

12 December 2020

Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.

1 reference

12 December 2020

Preclinical characteristics of gemcitabine.

1 reference

12 December 2020

Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK).

1 reference

12 December 2020

Does saturable formation of gemcitabine triphosphate occur in patients?

1 reference

12 December 2020

10.2165/11532970-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

12 November 2017

1020077734

0 references

1 reference